This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Repros Therapeutics, Inc.
Drug Names(s): Progenta, CDB-4124, Telapristone
Description: BioMedTracker has separate drug profiles for Proellex (oral) and Proellex-V (intravaginal).
Proellex is a selective progesterone receptor modulator (SPRM) which does not induce a low estrogen state.
A characteristic that distinguishes SPRMs from receptor full agonists (such as progesterone) and full antagonists is that their action differs in different tissues (agonist in some while antagonist in others). In preclinical study, Proellex has shown less antiglucocorticoid activity than another SPRM, mifepristone.
Repros and NIH
In 1999, Repros licensed rights to Proellex from the NIH under an exclusive, worldwide license in the field of treatment of human endocrinologic pathologies or conditions in steroid sensitive tissues. Under the terms of the agreement, Repros is obligated to meet developmental milestones as outlined in a commercial development plan. This development plan outlines a preclinical and clinical program leading to the stated objective of submitting an NDA for regulatory approval of Proellex for the treatment of uterine fibroids. In July 2002, Repros and the NIH amended the license agreement to include a revision of the original commercial development plan relating to the targeted dates for certain objectives. Additional updates of the original commercial development plan have been reached with the NIH thereafter in order to expedite development.
In July 2009, Repros announced that it entered into the Sixth Amendment to its Agreement with NIH relating to...See full deal structure in Biomedtracker
Partners: Gedeon Richter Plc
Proellex (Oral) News
Additional information available to subscribers only: